drugset / Trial / NCT02824575
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Phase 1
Terminated
28 enrolled
Montefiore Medical Center
Albert Einstein College of Medicine · collabDeciphera Pharmaceuticals, LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.
Timeline
- Start
- 2016-07
- Primary completion
- 2021-12-27
- Completion
- 2021-12-27
Outcome
Outcome not reported
Stopped: “Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are terminating early.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Subject | Rebastinib | Small molecule | 50 mg | Oral |
| Subject | Rebastinib | Small molecule | 100 mg | Oral |